Frontline Treatment Options Available for Patients With CLL
Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.
Jennifer Woyach, MD, an associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer CenterJames, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia (CLL).
There are a number of options in the first-line setting for patients with CLL, Woyach says. In terms of targeted therapies, ibrutinib (Imbruvica) can be used on its own as a single agent and most often is. However, acalabrutinib (Calquence), another BTK inhibitor, can be used with or without Obinutuzumab (Gazyva). There is also data on venetoclax (Venclexta) in combination with obinutuzumab.
Chemoimmunotherapy options are still considered, such as the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. FCR is considered especially for younger patients with IGVH-mutant CLL. Bendamustine/rituximab and chlorambucil/obinutuzumab are also still available, but Woyach says there are not a lot of scenarios where these would be used now.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
